Biovitrum AB acquired Swedish Orphan International Holding AB for approximately SEK 1.9 billion ($493M) in cash and shares, creating Swedish Orphan Biovitrum (Sobi), a leading European rare disease company focused on hemophilia, inflammation, and genetic diseases.